Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
After finishing at $10.26 in the prior trading day, Kura Oncology Inc (NASDAQ: KURA) closed at $10.44, up 1.75%. In other words, the price has increased by $1.75 from its previous closing price. On the day, 1.34 million shares were traded. KURA stock price reached its highest trading level at $10.6717 during the session, while it also had its lowest trading level at $10.2001.
Ratios:
Our goal is to gain a better understanding of KURA by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.44 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.38. For the most recent quarter (mrq), Quick Ratio is recorded 6.16 and its Current Ratio is at 6.16. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
On October 24, 2024, UBS started tracking the stock assigning a Buy rating and target price of $27.UBS initiated its Buy rating on October 24, 2024, with a $27 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 29 ’25 when WILSON TROY EDWARD bought 36,615 shares for $9.05 per share.
LEONI MOLLIE bought 12,314 shares of KURA for $111,442 on Sep 29 ’25. On Sep 29 ’25, another insider, POWL BRIAN T, who serves as the Officer of the company, bought 8,891 shares for $9.05 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KURA now has a Market Capitalization of 906162560 and an Enterprise Value of 294907616. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.88 while its Price-to-Book (P/B) ratio in mrq is 2.97. Its current Enterprise Value per Revenue stands at 3.541 whereas that against EBITDA is -1.348.
Stock Price History:
The Beta on a monthly basis for KURA is 0.35, which has changed by -0.38151658 over the last 52 weeks, in comparison to a change of 0.19088471 over the same period for the S&P500. Over the past 52 weeks, KURA has reached a high of $19.73, while it has fallen to a 52-week low of $5.41. The 50-Day Moving Average of the stock is 16.90%, while the 200-Day Moving Average is calculated to be 43.32%.
Shares Statistics:
The stock has traded on average 1.85M shares per day over the past 3-months and 2110080 shares per day over the last 10 days, according to various share statistics. A total of 86.80M shares are outstanding, with a floating share count of 83.75M. Insiders hold about 3.51% of the company’s shares, while institutions hold 94.33% stake in the company. Shares short for KURA as of 1760486400 were 10610088 with a Short Ratio of 5.75, compared to 1757894400 on 10849204. Therefore, it implies a Short% of Shares Outstanding of 10610088 and a Short% of Float of 12.25.
Earnings Estimates
Kura Oncology Inc (KURA) is presently subject to a detailed evaluation by 9.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.16, with high estimates of $0.65 and low estimates of -$1.0.
Analysts are recommending an EPS of between -$0.4 and -$3.39 for the fiscal current year, implying an average EPS of -$2.23. EPS for the following year is -$2.24, with 9.0 analysts recommending between -$0.37 and -$4.93.
Revenue Estimates
A total of 14 analysts have provided revenue estimates for KURA’s current fiscal year. The highest revenue estimate was $453.9M, while the lowest revenue estimate was $29.4M, resulting in an average revenue estimate of $148.79M. In the same quarter a year ago, actual revenue was $53.88MBased on 14 analysts’ estimates, the company’s revenue will be $201.18M in the next fiscal year. The high estimate is $451.2M and the low estimate is $20.05M.
